FibroGen, Inc.
United States
237 articles about FibroGen, Inc.
-
FibroGen Reports Second Quarter 2020 Financial Results
8/6/2020
FibroGen, Inc. reported financial results for the second quarter of 2020 and provided an update on the company’s recent developments.
-
FibroGen Announces New Appointments to its Board of Directors
8/6/2020
Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute
-
FibroGen to Report Second Quarter 2020 Financial Results
7/23/2020
FibroGen, Inc. will announce its second quarter 2020 financial results on Thursday, August 6 after the market close.
-
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
6/23/2020
FibroGen, Inc. announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute coronavirus 2019 infection.
-
FibroGen Appoints Thane Wettig as Chief Commercial Officer
6/22/2020
FibroGen, Inc. announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more than 30 years of global biopharmaceutical leadership and experience.
-
FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress
6/8/2020
FibroGen, Inc. (NASDAQ:FGEN) announced data from three roxadustat clinical trials, including the Phase 3 DOLOMITES study evaluating roxadustat for treatment of anemia in non-dialysis-dependent CKD patients compared to darbepoetin alfa, and ophthalmology findings from a Japan Phase 3 study evaluating roxadustat compared to darbepoetin alfa in patients on hemodialysis
-
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
6/8/2020
Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United States with Severe COVID-19
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
FibroGen to Present at Upcoming Investor Conferences in June 2020
5/27/2020
FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences
-
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
5/8/2020
FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May 12-14, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 11:00 AM Eastern Time on Thursday, May 14. A live audio webcast will be available on the “Events & Presentations” section of the FibroGen website at www.fibrogen.com. A replay of the fireside chat will be a
-
FibroGen Reports First Quarter 2020 Financial Results
5/7/2020
FibroGen, Inc. reported financial results for the first quarter of 2020 and provided an update on the company’s recent developments.
-
FibroGen To Report First Quarter 2020 Financial Results
4/24/2020
FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website at https:/
-
FibroGen Reports UK Court Ruling
4/20/2020
FibroGen, Inc. announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors to be invalid.
-
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
3/2/2020
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year of 2019 and provided an update on the company’s recent development
-
FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results
2/18/2020
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2019 financial results after market close on Monday, March 2, 2020. FibroGen will also conduct a conference call on that day at 5:00 p.m. (2:00 p.m. PT)
-
FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference
2/11/2020
FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 3:30 PM Eastern Time
-
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
2/11/2020
FibroGen, Inc. announced that the U.S. Food and Drug Administration has completed its filing review of its New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease, in both non-dialysis-dependent and dialysis-dependent patients.
-
Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan
1/30/2020
Astellas Pharma Inc. and FibroGen, Inc. announced the submission of a supplemental New Drug Application to Japan's Ministry of Health, Labour and Welfare to gain marketing approval for Evrenzo® for the treatment of anemia associated with chronic kidney disease in non-dialysis dependent patients.
-
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
-
BioSpace Movers & Shakers, Jan. 10
1/10/2020
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week's appointments.